1. Home
  2. CDXS vs MCR Comparison

CDXS vs MCR Comparison

Compare CDXS & MCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDXS
  • MCR
  • Stock Information
  • Founded
  • CDXS 2002
  • MCR 1989
  • Country
  • CDXS United States
  • MCR United States
  • Employees
  • CDXS N/A
  • MCR N/A
  • Industry
  • CDXS Major Chemicals
  • MCR Trusts Except Educational Religious and Charitable
  • Sector
  • CDXS Industrials
  • MCR Finance
  • Exchange
  • CDXS Nasdaq
  • MCR Nasdaq
  • Market Cap
  • CDXS 230.3M
  • MCR 266.0M
  • IPO Year
  • CDXS 2010
  • MCR N/A
  • Fundamental
  • Price
  • CDXS $2.11
  • MCR $6.04
  • Analyst Decision
  • CDXS Buy
  • MCR
  • Analyst Count
  • CDXS 2
  • MCR 0
  • Target Price
  • CDXS $11.00
  • MCR N/A
  • AVG Volume (30 Days)
  • CDXS 1.1M
  • MCR 66.7K
  • Earning Date
  • CDXS 05-01-2025
  • MCR 01-01-0001
  • Dividend Yield
  • CDXS N/A
  • MCR 8.52%
  • EPS Growth
  • CDXS N/A
  • MCR N/A
  • EPS
  • CDXS N/A
  • MCR 0.38
  • Revenue
  • CDXS $59,345,000.00
  • MCR N/A
  • Revenue This Year
  • CDXS $12.62
  • MCR N/A
  • Revenue Next Year
  • CDXS $22.11
  • MCR N/A
  • P/E Ratio
  • CDXS N/A
  • MCR $16.61
  • Revenue Growth
  • CDXS N/A
  • MCR N/A
  • 52 Week Low
  • CDXS $1.90
  • MCR $5.63
  • 52 Week High
  • CDXS $6.08
  • MCR $6.70
  • Technical
  • Relative Strength Index (RSI)
  • CDXS 35.96
  • MCR 42.07
  • Support Level
  • CDXS $1.91
  • MCR $5.90
  • Resistance Level
  • CDXS $2.47
  • MCR $6.08
  • Average True Range (ATR)
  • CDXS 0.21
  • MCR 0.12
  • MACD
  • CDXS 0.02
  • MCR -0.01
  • Stochastic Oscillator
  • CDXS 23.86
  • MCR 62.67

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

About MCR MFS Charter Income Trust

MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income. The fund invests the assets in debt instruments. It invests the assets in corporate bonds of U.S. and foreign issuers, U.S. Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S. and foreign issuers, and debt instruments of issuers located in emerging market countries.

Share on Social Networks: